FRAGMINE

This heparin is low molecular weight heparin (HBPM).Its indications are as follows: Adult population.

• Curative treatment of formed deep venous thrombosis (DVT);

• Treatment of unstable angina and myocardial infarction without Q-wave in acute phase, in combination with aspirin;

• Prevention of coagulation of the extracorporal circulation circuit during haemodialysis (general session of ≤ 4 hours).

Paediatric population

Treatment of symptomatic venous thromboembolism (VTE) in paediatric patients 1 month of age and older.

Although the various treatments for heparin-like drugs, including the low-molecular-weight drugs, have all levels expressed in international anti-Xa units, their efficacy is not limited to this anti-Xa activity.

It would be dangerous to substitute the regimen of one HBPM with that of another HBPM or that of another polysaccharide synthesis, each regimen having been validated by specific clinical studies.

Therefore, it is advisable to be particularly vigilant and to follow the specific directions for use of each of the specialties.

FRAGMINE should not be injected

Due to the risk of d-haematom, the intramuscular injection of other medicinal products should be avoided when the daily dose of dalteparin sodium is greater than 5,000 I. Special warnings The caution of the need for the medication is especially necessary in case of thrombocytopenia and d-d-abnormality of platelet function, severe hepatic and renal failure, uncontrolled hypertension or diabetic retinopathy.

Caution is also given to the need for the treatment of the disease or for the disease.

The following are the results of the study: odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsistic, odepsistic, odepsistic, odepsistic, odop.

Approximately 3% of patients receiving prophylactic treatment have been reported as a result of side effects.

Reported adverse reactions that may be related to dalteparin sodium are listed below by system organ classification and frequency: common ( 3 1/100, < 1/10), uncommon ( 3 1/1,000, < 1/100), rare ( 3 1/10 000).

System organ class Frequency Adverse reactions

Blood and lymphatic disorders Common Moderate thrombopenia (Type I), generally reversible during treatment Indeterminate Heparin-induced immunoallergic thrombocytopenia (Type II, with or without associated thrombotic complications) Immune system disorders Uncommon Absorbent hypersensitivity and disorder of the patient's peripheralness may be agitation of the patient's peripherality or agitation of the patient's peripherality may be agitation of the patient's peripherality may be agitation of the patient's peripherality may be angitation of the patient's peripherality may be angitation of the patient's peripherality may be angitation of the patient's peripherality may be agitation of the patient's peripherality may be agitation of which is.